FY2025 EPS Estimate for REGENXBIO Decreased by Analyst

REGENXBIO Inc. (NASDAQ:RGNX) – Equities research analysts at Chardan Capital reduced their FY2025 earnings per share (EPS) estimates for shares of REGENXBIO in a report issued on Wednesday, May 14th. Chardan Capital analyst D. Gataulin now forecasts that the biotechnology company will post earnings per share of ($3.25) for the year, down from their prior forecast of ($3.03). Chardan Capital currently has a “Buy” rating and a $52.00 target price on the stock. The consensus estimate for REGENXBIO’s current full-year earnings is ($4.84) per share.

REGENXBIO (NASDAQ:RGNX) last announced its quarterly earnings data on Monday, May 12th. The biotechnology company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.41 by ($0.29). The firm had revenue of $89.01 million for the quarter, compared to analysts’ expectations of $105.35 million. REGENXBIO had a negative net margin of 283.19% and a negative return on equity of 70.65%.

A number of other equities research analysts have also recently weighed in on the stock. HC Wainwright cut their price objective on shares of REGENXBIO from $36.00 to $34.00 and set a “buy” rating on the stock in a report on Monday, March 17th. The Goldman Sachs Group dropped their price target on REGENXBIO from $14.00 to $12.00 and set a “neutral” rating on the stock in a research report on Thursday, April 17th. Morgan Stanley raised their price objective on REGENXBIO from $22.00 to $24.00 and gave the company an “overweight” rating in a research report on Friday, March 14th. Raymond James started coverage on REGENXBIO in a research note on Friday, February 7th. They set an “outperform” rating and a $27.00 price objective for the company. Finally, Leerink Partners set a $24.00 target price on REGENXBIO in a research note on Tuesday, March 18th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, REGENXBIO presently has a consensus rating of “Moderate Buy” and a consensus price target of $31.63.

REGENXBIO Price Performance

Shares of REGENXBIO stock opened at $8.89 on Monday. REGENXBIO has a 1 year low of $5.04 and a 1 year high of $16.25. The firm has a market cap of $445.92 million, a price-to-earnings ratio of -1.77 and a beta of 1.11. The company has a 50-day moving average of $7.54 and a 200 day moving average of $7.97.

Insider Activity at REGENXBIO

In other news, Director Kenneth T. Mills sold 20,602 shares of the company’s stock in a transaction on Monday, May 12th. The stock was sold at an average price of $7.91, for a total transaction of $162,961.82. Following the transaction, the director now directly owns 475,103 shares of the company’s stock, valued at $3,758,064.73. This represents a 4.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 12.79% of the stock is owned by insiders.

Institutional Investors Weigh In On REGENXBIO

Large investors have recently bought and sold shares of the business. JPMorgan Chase & Co. boosted its holdings in shares of REGENXBIO by 67.0% during the 4th quarter. JPMorgan Chase & Co. now owns 4,136,517 shares of the biotechnology company’s stock valued at $31,975,000 after acquiring an additional 1,659,206 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of REGENXBIO by 16.3% during the first quarter. Vanguard Group Inc. now owns 3,472,988 shares of the biotechnology company’s stock valued at $24,832,000 after purchasing an additional 487,036 shares during the last quarter. Millennium Management LLC lifted its position in REGENXBIO by 406.3% during the fourth quarter. Millennium Management LLC now owns 1,322,344 shares of the biotechnology company’s stock valued at $10,222,000 after purchasing an additional 1,061,187 shares during the period. Balyasny Asset Management L.P. boosted its holdings in REGENXBIO by 6.0% in the fourth quarter. Balyasny Asset Management L.P. now owns 1,187,102 shares of the biotechnology company’s stock worth $9,176,000 after purchasing an additional 66,993 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its holdings in REGENXBIO by 1.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,171,422 shares of the biotechnology company’s stock worth $9,054,000 after purchasing an additional 21,234 shares during the last quarter. 88.08% of the stock is currently owned by institutional investors.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.